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ABSTRACT

Furman, Amanda René. M.S., Department of Pharmacology/ Toxicology, Wright State
University, 2012. Evaluation of CM-2,525 as a neuroprotectant against sarin: A
comparison with 8-OH-DPAT.

Exposure to the chemical warfare agent sarin produces long term neurological deficits.
The long term medical consequences could be averted with the development of
neuroprotectants to preserve brain function. In our mouse model, the combination of the
carboxylesterase inhibitor 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorin-2-oxide (CBDP)
with the organophosphorus (OP) nerve agent sarin was used to render mice more
sensitive to poisoning and reduce the amount of hydrogen fluoride cleaved from sarin
during binding to esterases. Since carboxylesterase acts as a scavenger, reducing the
levels causes sarin to have a greater inhibition effect on acetylcholinesterase. These
smaller doses permitted the use of doses similar to those producing symptoms in humans.
Prior work demonstrated that 8-OH-DPAT (DPAT) was neuroprotective when given up
to two hours after sarin administration through its secondary pharmacology. The aim of
this study was to explore the efficacy of CM-2,525, which acts on part of that secondary
pharmacology, as a neuroprotectant and to directly compare its effects with DPAT. Male
C57BL/6 mice were administered a toxic challenge of 1.5 mg/kg of CBDP plus the dose
of sarin needed to achieve 35% mortality. A dose-response curve for CM-2,535 was
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determined by administration one minute after the toxic challenge. Male C57BL/6 mice
also were administered a toxic challenge followed in one minute by saline or DPAT (1
mg/kg). Functional Observational Battery (FOB) data were collected for each mouse and
weight data were collected pre- and post-exposure for 3 days. Treatment with DPAT
revealed no benefit on FOB scores and had no effect on weight loss. Low doses of CM2,525 reduced the FOB scores and the higher doses decreased weight loss.
Immunohistological analysis was performed using Glial Fibrillary Associated Protein
(GFAP) which increases in sarin treated animals and Neuronal Nuclei (NeuN), a stain for
mature neurons that decreases after toxic challenge. Previously we found that treatment
with DPAT resulted in a significant decrease in GFAP-labeled cells in the dentate gyrus
(DG) and is effective when given two hours after the toxic challenge. In this study it both
reduced GFAP and increased NeuN. The higher doses of CM-2,525 significantly
decreased GFAP-labeled cells in the amygdala (Amy) and DG regions and increased
NeuN-labeled cells in the Amy, piriform cortex, and DG regions. CM-2,525 has efficacy
superior to DPAT with effects on weight loss and FOB scores as well as providing
neuroprotection and would likely be neuroprotective as long after sarin exposure as
DPAT.
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I. Introduction
Background and history
The nerve agents, also known as organophosphorus (OP) compounds, were first
synthesized by the Germans prior to World War II (Sidell, Newmark, & McDonough,
2008). The compounds, organic esters derived from phosphoric acid, are some of the
deadliest compounds made by man for use against man (Grob & Harvey, 1953; Wiener &
Hoffman, 2004). The German scientist Dr. Gerhard Schrader synthesized the first
compound in 1936 while looking for a stronger pesticide; the new pesticide was found to
be more potent and extremely toxic to humans. By the end of WWII, other agents were
developed. Four major OP compounds were developed: tabun (GA), sarin (GB), soman
(GD), and VX, each differing in potency and volatility (Solberg & Belkin, 1997). The G
agents were developed in Germany and VX in Britain (Wiener & Hoffman, 2004).
During WWII, the Germans created a production facility to manufacture sarin and
tabun for use during the war. The agents were stockpiled but were not used. After the
war, the Soviet forces annexed the production facility and Allied forces uncovered nerve
agents stored in munitions. The potential of the agents was recognized and stockpiles
were developed by the Soviet Union and the United States. The first battlefield use of
sarin and tabun occurred in 1988 by the Iraqis against Iranian forces. The first reported
terrorism use of nerve agents was in 1994 (Sidell et al., 2008; Wiener & Hoffman, 2004).
Sarin was implemented by the terrorist organization Aum Shinrikyo in Japan in two
separate incidences. The first release on June 27, 1994 was targeted against three judges
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in the city of Matsumoto. Seven people were killed and nearly 500 were sent to the
hospital. The second release was in the Tokyo Subway on March 20, 1995. Packages of
sarin were placed on five different trains converging on Tokyo; 12 people were killed and
one thousand were injured (Olson, 1999).
Sarin, isopropyl methylphosphonofluoridate, is a colorless, odorless, volatile
liquid. Of the agents, sarin is the most volatile with a vapor pressure similar to water.
Since the vapors are heavier than air and they sink to the ground (Weinbroum, 2004;
Wiener & Hoffman, 2004). Sarin is liquid at room temperature with a boiling point of
158° C, the lowest boiling point of all the nerve agents and persists in the environment
from 2-24 hours depending on temperature, humidity, and wind (Wiener & Hoffman,
2004; Sidell et al., 2008). Once dispersed, the nerve agent is absorbed through the skin,
eyes, or respiratory tract and distributes rapidly in tissues. The biological effects are
related to the phosphorylating abilities of the nerve agents (Abu-Qare & Abou-Donia,
2002).
The threat of an attack using nerve agents still exists today. Given the previous
use by Aum Shinrikyo and use in the Iraqi-Iran war in the 1980s, sarin is the nerve agent
most likely to be used in a future attack. Sarin is the most volatile of the nerve agents and
is relatively easy to manufacture. The formula and methods for synthesis can be found on
the internet and in research articles; one was written by Abu-Qare and Abou-Donia
(2002). Due to the ease of finding the methods and the ease to manufacture, there is
potential for use by terrorist organizations or by countries in which we are at war.
Symptoms
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Nerve agents can be dispersed as a vapor, spray, aerosol, adsorbed as dust, or
made into solutions; therefore, exposure can be by inhalation, dermal absorption,
digestion, or injection routes. It has been estimated that the lethal exposure amount is
about 30-50 times the dose that induces symptomatic exposure (Grob, 1956). Symptoms
are due to the inhibitory effects of nerve agents on acetylcholinesterase (AChE) and
subsequent activation of the nicotinic and muscarinic acetylcholine (ACh) receptors. The
muscarinic effects are the first to appear. Symptoms include salivation, lacrimation,
urination, defecation, diaphoresis, and emesis. Bronchorrhea (watery sputum),
bronchoconstriction, and bradycardia with tightness in the chest and heartburn are the
more life-threatening effects. Nicotinic effects follow the muscarinic symptoms.
Nicotinic manifestations are due to the elevated ACh levels at the neuromuscular
junction. Symptoms include increased fatigability, mild to severe generalized weakness,
involuntary muscle twitching, scattered muscular fasciculation, flaccid paralysis, and
paralysis of the diaphragm and chest wall muscles (Grob, 1956; Wiener & Hoffman,
2004).
Neurotoxicity
Central nervous system manifestations are marked by convulsions. Symptoms can
be broken down into three main categories: neuropsychiatric disorders, convulsions, and
respiratory depression. The neuropsychiatric disorders include tension, anxiety,
jitteriness, restlessness, emotional instability, and giddiness (Lemercier, Carpentier,
Sentenacroumanou, & Morelis, 1983). With moderate exposure, insomnia with excessive
dreaming can occur. Extensive exposure results in headache, tremor, drowsiness,
difficulty in concentrating, and a slowness of recall and mental confusion (Grob &
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Harvey, 1953). The neuropsychiatric disorders are followed by convulsions, coma, and
then death if not treated (Lemercier et al., 1983). Death occurs due to depression of the
central respiratory drive and the consequential respiratory failure (Dunn & Sidell, 1989).
If treatment is obtained, symptoms may be lessened, but a complete recovery is unlikely
and improvement is slow. Chronic symptoms involve similar symptoms as is seen with
extensive exposure (Abou-Donia, 2003).
Convulsions are a major indicator of OP intoxication. Seizures rapidly progress to
status epilepticus, which is unremitting seizures, and causes brain damage (Solberg &
Belkin, 1997). Seizure activity is thought to originate at the muscarinic receptors in the
piriform cortex and spreads through the hippocampus towards the thalamus (Tattersall,
2009). Damage to brain structures occurs in several brain areas including the pyramidal
layer of the hippocampus, the piriform cortex, the thalamus, and the amygdaloid complex
(Lemercier et al., 1983). Severe damage is not evident by gross histopathology alone, as
no lesion develops (Grob, 1956). This makes it necessary to stain for neurodegeneration
markers to see the damage and to use a functional observational battery to detect effects.
Mechanism
The effects of sarin are primarily due to the inhibition of AChE and the
accumulation of ACh in the peripheral and central nervous system. The neurotransmitter
ACh is released in response to nerve stimulation and binds post-synaptically to ACh
muscarinic and nicotinic receptors resulting in muscle contraction or gland secretions
(Abu-Qare & Abou-Donia, 2002). Muscarinic receptors are found at postganglionic
parasympathetic nerve endings, on sympathetic receptors for sweat glands, in the heart,
and the CNS. The nicotinic receptors innervate the sympathetic and parasympathetic

4	
  

	
  
	
  

ganglion, the neuromuscular junction, and the CNS (Wiener & Hoffman, 2004). The
normal function of AChE enzymes is to hydrolyze acetylcholine leading to the
breakdown and reduction in concentration of the neurotransmitter at the neuromuscular
junction or the synapse. ACh binds to the active site of the enzyme and undergoes a
hydrolysis reaction by the serine hydroxyl, releasing choline and acetate. Acetate is
covalently bonded to the serine forming an acetylated enzyme intermediate. Water binds
to the intermediate releasing acetate and reactivates the enzyme (Wiener & Hoffman,
2004; Abu-Qare & Abou-Donia, 2002).
Sarin, a potent inhibitor of AChE, binds to the enzyme allowing ACh to
accumulate (Grob, 1956). When sarin binds, it phosphorylates the serine hydroxyl group
on the active site. The phosphoric ester formed is stable and hence the isopropyl group on
sarin does not undergo hydrolysis and the enzyme becomes irreversibly inactivated, a
process known as aging (Dunn & Sidell, 1989; Abou-Donia, 2003). The time until aging
occurs varies among the nerve agents with an aging half-time of 5 hours for sarin
(Wiener & Hoffman, 2004). A new AChE enzyme must be synthesized in order for ACh
to be broken down. The first stage of toxicity, the acute cholinergic syndrome, occurs
when 75% of the AChE enzymes are permanently inactivated (Abu-Qare & Abou-Donia,
2002).
The first step in the mechanism of seizures of OP exposure involves an early
cholinergic phase, which lasts up to 5 minutes after seizure onset. The cholinergic stage is
characterized by the accumulation of ACh and is proposed to be the seizure initiator. The
seizure then progresses into a transitional phase, which consists of cholinergic and
noncholinergic components and lasts for 40 minutes after onset. Other changes in
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neurotransmission occur in the transitional stage. Changes in NE, DOPAC, HVA,
glutamate, DA, 5-HT, 5-HIAA, and GABA are seen from 5 minutes to hours after seizure
onset. The increase in glutamate occurs in the limbic system immediately and is initiated
by the muscarinic receptors. NE depletion occurs, DA turnover increases, and GABA
functions are impaired. The final stage, after 40 minutes, is noncholinergic in nature. In
the final stage, the extracellular levels of ACh return towards normal. Increases in DA
and GABA are still observed after 40 minutes, while increases in 5-HIAA and the 5-HT
turnover rate increases from 2-4 hours (Tattersall, 2009). Sustained seizure activity is
speculated to result from the excessive amounts of glutamate released. Glutamate is
presumed to stimulate the continued release of ACh contributing to the extended seizure
activity (Solberg & Belkin, 1997).
Three hypotheses have been suggested to explain the neuropathology after OP
exposure. The excitotoxic theory uses the prolonged seizure activity as the main cause.
Hypoxic factors, to explain changes in oxygenation and blood flow to the brain, are the
second hypothesis. Direct toxic action on the neurons by the OPs is the third (Tattersall,
2009). The increase in glutamate may play a role in the neurodegeneration seen after OP
exposure and may be evidence for the excitotoxic theory. Glutamate, through ionotropic
NMDA and non-NMDA receptors, causes an influx of sodium and potassium into the
neuron. The resulting depolarization of the membrane facilitates calcium influx, which
induces neuronal death via deterioration of cellular metabolism (Peruche, Backhauß,
Rehn, & Rieglstein, 1994).
Therapeutics
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Developing treatments is still ongoing research. The aim of prophylaxis thus far
has been on resistance against nerve agents, pre-treatments, and to stop or minimize the
toxic effect. To minimize toxic effects, researchers have focused on AChE inhibition,
including scavengers, reversible AChE inhibitors, and AChE reactivators, and
anticholinergics to combat the ACh accumulation (Bajgar, Fusek, Kassa, Kuca, & Jun,
2009). Currently there are four classes of therapeutics used in the treatment of OP
exposure: anticholinergics, oximes, anti-convulsants, and pretreatments. The
pretreatments used include carbamates and scavengers.
Since nerve agents were first developed, atropine has been the basis for therapy
(Dunn & Sidell, 1989). Atropine, derived from Atropa belladonna (deadly nightshade), is
the primary drug given after acute OP poisoning. As a competitive antagonist of the
muscarinic receptor, atropine is only efficacious for the muscarinic effects and not the
nicotinic effects. Atropine has limited penetration into the CNS sufficient only to block
convulsions for a limited time (Husain, Ansari, & Ferder, 2010). Other anti-muscarinic
drugs were developed with greater ability to cross the blood brain barrier, but they have
worse adverse effects if given when nerve agents are not present. The increased toxicities
led to the rejection of these drugs for treatment and the continued use of atropine (Wiener
& Hoffman, 2004).
Oximes are used for AChE reactivation and act on the nicotinic effects: muscle
fasciculations and reverse the paralysis of respiratory muscles (Dunn & Sidell, 1989).
They work by binding to the AChE enzyme reversibly. Competition between the oxime
and the nerve agent occurs and proceeds with the eventual release of the inactivated nerve
agent from the enzyme. Reactivation of the enzyme transpires when the nerve agent is
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removed from the enzyme, but is only effective if aging of the enzyme has not occurred.
Currently, 2-pyridine aldoxime methyl chloride (2-PAM) is the oxime of choice for
treatment (Weinbroum, 2004). Some newly tested oximes can pass the blood brain barrier
and possibly help with CNS symptoms, though the effectiveness has not been extensively
measured (Stojiljkovic & Jokanovic, 2006). At this time a universal oxime capable of
protecting against all known organophosphates does not exist. Oximes are not as
effective when used alone, though are more efficacious when atropine is co-administered
(Stojiljkovic & Jokanovic, 2006).
Anticonvulsants are considered essential to enhance the current treatment as
seizures do not respond well to atropine and oximes. The combination of atropine, an
oxime, and a benzodiazepine is more efficacious than atropine or oxime alone in
improving survival. Diazepam is currently used to stop convulsions brought on by OP
poisoning (Weinbroum, 2004). The benzodiazepine class binds allosterically to GABA
receptors, depressing the CNS and thereby decreasing seizures through post-synaptic
targets involved in the seizure process. GABAergic-based anticonvulsants hyperpolarize
the neurons making them less prone to depolarization. GABA agonists, such as the
benzodiazepine class, work on non-ACh mechanisms as well as the indirect effects on
ACh receptors. Diazepam is also useful in reducing the anxiety, restlessness, and muscle
fasciculations associated with nerve agent exposure (Husain et al., 2010). Pentobarbital,
another GABA allosteric agonist, was effective against seizures when treatment was
delayed 40 minutes. However, severe respiration side effects are observed after seizures
due to a post-ictal depression characterized by suppression of the respiratory system
(Myhrer, Andersen, Nguyen, & Aas, 2005). Current research has focused on NMDA
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receptor antagonists for treatment of the prolonged convulsions. Non-competitive NMDA
antagonists were investigated as post-exposure treatment. MK-801 is more potent as an
anticonvulsant than diazepam. Blockage of the NMDA receptor by MK-801 prevents
excitatory neuronal activity and can block seizures by this mechanism. However, NMDA
antagonists have their own neurotoxic effects at other sites, precluding their use as a
therapeutic response (Ballough, Newmark, Levine, & Filbert, 2008; Olney et al., 1991).
Ketamine afforded some protection when given 30 minutes after exposure, but multiple
doses were required if treatment was delayed further. Two or three doses given one hour
post-exposure improved survival but were not effective in preventing seizure remittance.
Further delay in treatment resulted in a reduction of the protection afforded at the earlier
time points (Dorandeu et al., 2005). The use of NMDA antagonists, thus far, has resulted
in protection and toxic side effects and is only effective when multiple doses are given
for up to one hour post-exposure.

Pyridostigmine, a carbamate, is commonly used in

the military as a pretreatment against a hostile environment if soman poisoning is
suspected. The spontaneous reversibility of carbamate binding to AChE protects a
proportion of the enzyme from attack by nerve agents. By protecting a portion of AChE,
the enzyme can be reactivated offsetting the additive toxicity. Pyridostigmine does not
penetrate deeply into the CNS but rather, provides protection to the peripheral nervous
system. The protection provided by treatment with pyridostigmine is not uniform and is
not effective without the use of antidotes, such as atropine and 2-PAM. For this reason,
pyridostigmine is considered a pretreatment adjunct and not a pretreatment by itself
(Dunn & Sidell, 1989).
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Recently, research has focused on the use of scavengers as a possible treatment.
Scavengers can be either catalytic, enzymes that split the OP, or stoichiometric, enzymes
that bind the OP. Butyrylcholinesterase (BuChE) and AChE from plasma were effective
in protecting against OP intoxication. The enzyme works at the beginning of the toxic
response and does not tend to interact with tissues so few side effects are seen. BuChE as
a pretreatment was effective against low levels of sarin exposure (Bajgar et al., 2009).
However, the majority of research used scavengers as a pretreatment and found them
ineffective as post-exposure treatments.
Combining treatments appears to be the most effective plan at this time. The
current treatment methodology involves a combination of drugs to increase survival. The
standard pretreatment is pyridostigmine to shield a fraction of ChE. Atropine is then
given to antagonize ACh at the muscarinic receptors. 2-PAM, an oxime, is given to
reactivate the un-aged enzyme. An anticonvulsant, in particular diazepam, is used to
control seizure activity. The combination approach to treatment of acute OP poisoning is
the most effective for a reduction of mortality (McDonough & Shih, 1997).
Need for new therapies
A novel therapeutic for chemical weapons is long overdue. The standard
treatment of atropine, oxime, and an anticonvulsant has been the mainstay regimen since
the chemical warfare agents were first developed. Improvements need to be made in
treatments against the neurotoxicities and ensuing brain damage.
Atropine, or other anticholinergics, must be administered immediately after
symptoms present. The anticholinergics studied are effective as a pretreatment and when
given shortly after seizure onset. An increase in dose may be required to have the same
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effect after 5 minutes of seizure (McDonough & Shih, 1997). When treatment with
anticholinergics is delayed by 20 minutes after seizure onset they are no longer effective.
Some newer drugs are effective after a 40 minute delay. Atropine only has peripheral
effects on the muscarinic receptor; central efficacy is seen in very high doses only. Side
effects of atropine occur with high doses or if nerve agents are not present in the system
and include dry mouth, difficulty swallowing, mild drowsiness, slowing of motor
activity, and blurred vision (Grob, 1956). Scopolamine, a newly studied anticholinergic,
works on both the periphery and central effects, however elimination is quick and adverse
side effects are seen if nerve agents are not present (Bajgar et al., 2009).
The biggest problem with oximes is that they must be given before aging occurs
(Weinbroum, 2004). The current oximes being tested are not capable of affording
protection against all OPs (Stojiljkovic & Jokanovic, 2006). Thus, oximes must be given
either as a pretreatment or alongside atropine shortly after indication of exposure.
The anticonvulsants are only effective during the first 20 minutes after seizure
onset. After treatment with benzodiazepines, seizure activity can reoccur so that multiple
doses may be required. A side effect of the benzodiazepine is respiratory depression,
which can be more detrimental to survival (Tattersall, 2009). With the recurrence of
seizures after diazepam treatment, protection against brain damage is not complete.
Pyridostigmine does not provide protection by itself and is only effective as a
pretreatment (Dunn & Sidell, 1989). Reactivators that are used as pretreatments are
ineffective immediately and have a low affinity for the enzyme. To be effective,
reactivators must be taken minutes after exposure (Bajgar et al., 2009). Scavengers like
BuChE are effective but must be given as a pretreatment. The stoichiometric enzymes
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require a 1:1 ratio of scavenger to OP molecule to offer adequate protection, which
requires large doses.
The current treatments are inadequate at providing reduced lethality and do not
offer neuroprotection. There is a lack of efficacious treatments after 20 minutes for OP
exposure and the current treatments are inadequate at providing reduced lethality. The
effects of anticonvulsant drugs are temporary unless the underlying mechanism is
corrected. The current treatment regimen does not offer neuroprotection by the
prevention of seizure activity or motor convulsions. A better therapeutic is required to
provide neuroprotection from the prolonged convulsions. There is a requirement for
treatments that are efficacious after the 20 minute mark when the other therapies are no
longer effective.

Figure 1: Theorized mechanism for sarin neurotoxicity and where treatment is viable.
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Use of CBDP in the research model
Carboxylesterases (CaE) are enzymes in the same family as cholinesterases. The
CaE enzymes, found in the blood and nearly all organs, bind stoichiometrically to OP
molecules (Wheelock et al., 2008). The enzymes act as scavengers to OPs and offer
protection for AChE enzymes. Rodents have a higher level of CaE than humans. The
higher levels of CaE in rodents allow for more sarin to be detoxified than would be in
humans. By using the CaE inhibitor 2-(O-cresyl)-4H-1:3:2-benzodiox- aphosphorin-2oxide (CBDP), CaE was blocked allowing the free OPs to inhibit more critical enzymes,
like AChE (Jimmerson, Shih, Maxwell, Kaminskis, & Mailman, 1989). With less CaE
available to inactivate sarin, a smaller sarin dose is more effective at inhibiting AChE and
directly killing the cells. Using a lower dose of sarin provides a better representation of
the effects seen in humans. A dose of 1.5 mg/kg of CBDP inhibits CaE by 80% in one
hour with no effect on AChE activity in the blood or brain (Garrett, Rapp, Grubbs,
Schlager, & Lucot, 2010).
8-OH-DPAT as a neuroprotectant
8-OH-DPAT (DPAT) is a serotonin 1A (5-HT1A) receptor agonist. Early work
with 5-HT1A receptor agonists was performed in 1997 using BAYx3701, now known as
repinotan. The neuroprotective role repinotan plays on ischemia and traumatic brain
injury was assessed. Repinotan was found to have long-lasting neuroprotective effects in
animal models of ischemic stroke. Early studies verified that 5-HT1A receptor agonists
were effective in pathways leading to neuroprotection and neuronal function (Berends,
Luiten, & Nyakas, 2005).
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Binding sites for 5-HT1A are present in the basal ganglia, the midbrain, the spinal
cord, and widely throughout the brain and serve multiple functions (Barnes & Sharp,
1999). DPAT has been studied as a neuroprotectant in stroke and NMDA-induced
excitotoxicity. The mechanism of protection has not been determined. It is thought that
DPAT and other 5-HT1A agonists stimulate astroglial cells (Harkany et al., 2001). Others
noticed a reduction in glutamate release with the administration of DPAT against
ischemic brain damage (Alessandri, Tsuchida, & Bullock, 1999). Another explanation for
the neuroprotective effects is due to activation of PKC-α via the ERK pathway. The ERK
pathway induction leads to caspase-3 inhibition and a reduction in apoptosis (Adayev,
Ray, Sondhi, Sobocki, & Banerjee, 2003).
The use of DPAT as a neuroprotectant has been studied in stroke and
excitotoxicity models. Oosterink et al (2003) found that DPAT may counteract
excitotoxic neural injury when used as a pretreatment or a post-treatment. Treatment with
DPAT 6 hours after NMDA-induced excitotoxicity resulted in improved behavioral
recovery and an increase in cholinergic density, a sign of neuroprotection. A study on
NMDA-induced stroke revealed a reduction in frequency of immobility when given up to
6 days after NMDA infusion (Harkany et al., 2001). In stroke studies, DPAT offered
neuroprotection and improved neurobehavioral performances (Kline, Yu, Horvath,
Marion, & Dixon, 2001). Mauler and Horyáth found the DPAT had a therapeutic window
of at least 5 hours against stroke, and others have found a therapeutic window of 2-4
hours as a neuroprotectant in stroke (2005).
Previously in our laboratory we found 8-OH-DPAT to be efficacious as a
neuroprotectant after sarin exposure. Treatment with 1 mg/kg DPAT 2 hours after sarin
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resulted in a lower mortality rate and a decrease in astrocytes, as indicated by a decrease
in glial fibrillary acidic protein (GFAP) staining. Changes in body weight over three days
and the Functional Observational Battery (FOB) scores were not affected by treatment
with DPAT (Joshi, 2009).
The ideal neuroprotectant would result in a decrease in FOB scores and a lack of
change in body weight along with the decreases in GFAP staining and increases in
neuronal nuclei (NeuN) staining. The purpose of the present study was to compare
another drug, CM-2,525, with DPAT for use as a possible neuroprotectant.
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II. Hypothesis
Development of hypothesis
The current treatments for sarin exposure are only effective if given 40 minutes
after symptoms and do not offer neuroprotection. Previous work in our lab found that 8OH-DPAT was effective at reducing the levels of glial fibrillary protein (GFAP) in the
dentate gyrus when given 2 hours after exposure. The effects of 8-OH-DPAT were not
reversed by treatment with a 5-HT1A antagonist suggesting that DPAT’s secondary
pharmacology provided the neuroprotection.
Hypothesis
CM-2,525 will act on the secondary pharmacology affected by DPAT to provide
neuroprotection from sarin seizure-induced neuronal damage in a dose-dependent and
time-response manner.
Aim 1
To test the hypothesis that CM-2,525 has efficacy comparable to DPAT in
providing neuroprotection by determining a dose response curve with CM-2,525
administered one minute after toxic challenge with sarin and comparing with the standard
dose of DPAT.
Aim 2
To test the hypothesis that CM-2,525 has efficacy in providing neuroprotection at
time points comparable to DPAT by determining a time-response curve
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III. Methods
Animals
Male C57BL/6 mice, age 6-8 weeks, weighing 20-25 grams were acquired from
Harlan Laboratories (Indianapolis, IN). Mice were housed in single cages and maintained
on a 12 hour light/dark cycle. Standard pellet rodent diet and water were available ad
libitum. Mice were allowed a 7 day acclimation to the facility before dosing. Mice used
in behavioral studies were handled for three days prior to dosing. Handling over several
days prior to experimentation habituates them to the stresses of injections and being
removed from the home cage (Hogg, 1996). The procedures were approved by the
Laboratory Animal Care and Use Committee at Wright State University, Dayton, OH.
Mice were euthanized 14 days post-injection via CO2 and decapitation. Frontal cortex
(FC) tissue was taken to measure cholinesterase activity as described below and whole
brains used for evaluation of neuropathology.
Treatment
Mice were injected with 1.5 mg/kg 2-(O-cresyl)-4H-1:3:2-benzodioxaphosphorin-2-oxide (CBDP) subcutaneously. This dose was determined previously to
inhibit CaE but not AChE or BuChE. The CBDP was diluted using a 10% ethanol and
propylene glycol solution. One hour later, mice were injected with sarin (USAMRICD,
Aberdeen Proving Ground, MD) subcutaneously. The sarin was diluted with 0.9% saline
with an injection volume of 0.5 mL/ 100 g. The dose of sarin used was determined prior
to each experiment to be the LD50 based on that dilution series and mouse shipment
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(43.7 µg/kg, 38.5 µg/kg, and 50.7 µg/kg). One minute following sarin injection, mice
were treated with varying doses of CM-2,525 to determine the dose response curve or
saline as a control. For comparison with prior data, 1 mg/kg of 8-OH DPAT was given
one minute following sarin injection. DPAT was made in an injection volume of 0.5 mL/
100 g and diluted with 0.9% saline. The drug CM-2,525 was diluted with distilled deionized water (DDI), with an injection volume of 0.5 mL/ 100 g. The CM-2,525 doses
were as follows: 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg. Both saline and CM2,525 were administered via an intraperitoneal (IP) injection, while DPAT was
administered via a sub-cutaneous injection (sc). Doses were not corrected for the salt.
Functional Observational Battery (FOB)
FOB’s were scored following injections. Each animal was given a sheet on which
we score gait, posture, breathing, eyes, and motor behavior. Times of first seizure and
time of death are recorded because a correlation between the severity of convulsions and
degeneration in the hippocampus was found after soman exposure (Filliat et al., 2007).
Scores are collected 15 minutes, 30 minutes, 45 minutes, 1 hour, 2 hours, 4 hours, and 24
hours after the sarin injection. Scores (out of 4, or 3 for breathing) are added together for
each time point. An additional score is added for whether death occurred at the interval.
The highest score for the first hour is reported. Percentages are calculated out of 21 total
points. FOB scores give an indication of how sick the animal is, with a higher score the
more sick the mouse. The FOB is a modification of Shih & Romano (1988) and Moser
(1995) and was modified by Garrett et al., (2010).
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Figure 2: FOB scoring sheet
Animal Weights
The threshold for severe weight impairment was determined to be 20% loss.
Weight loss was found to peak around day 2 or day 3 and was observed for 13 days
(Filliat et al., 2007). Body weights were taken previous to injection and for the following
three days. Any animals found dead were recorded in the animal book with the date they
were found. Changes in body weight at each day and percent change in body weight were
calculated; only 1 and 3 day time points were graphed. If an animal lost more than 25%
of its baseline body weight it was euthanized. Percent change in weight was determined
by subtracting the post-exposure weight (PW) on day 1 and day 3 from the baseline
weight (BW) and dividing by baseline weight (BW). The value was then multiplied by
100 to get percentage of weight loss, (((PW-BW)/BW)*100).
Behavior
Locomotor activity
The open field (OF) was used to examine general locomotor activity and
willingness to explore in rodents. Rodents prefer the periphery to the center of the arena.
Anxiolytic behaviors include an increase in time spent in the center with no differences in
the total locomotion or vertical activity. A decrease in time spent in the center with
increases in locomotion or vertical activity signifies an anxiogenic response (Prut &
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Belzung, 2003). Testing was done two days after injections in the morning. Mice were
carried into the testing room and left to acclimate for 15 minutes. The OF is an automated
system with infrared photo-beams consisting of a 16x16 inch (40.6x40.6 cm) plexiglass
square (Hamilton Kinder, Motor Monitor Version 3.11; Poway, CA). The arenas were
separated from view with the use of boards and curtains. Mice were placed in the center
open field arena and allowed to explore for 10 minutes. The OF arena was cleaned with
70% ethanol and dried after testing each mouse. Scores were recorded using the Kinder
Scientific MotorMonitor Software Package (Build 08356-14 Update 12jan2008). Data
were analyzed using the periphery vs. center settings. Scores for basic movements,
immobility, fine movements, X-ambulation, Y-ambulation, and periphery and center
distance (in), time (s), and rest time (s) were determined by IR beam interruptions. Basic
movements include larger body movements, while fine movements consist of headtwitching and grooming.
Elevated Plus Maze
The elevated plus maze (EPM) was used to assess anxiety-like responses in the
mice and is a useful preclinical screen for drugs with antianxiety activity. Rodents prefer
to explore in the closed arm portion of the maze. Forced or voluntary entry into the open
arms elicits an anxiogenic response. Anxiolytic drugs reduce the aversion and lead to an
increased time spent in the open arms. Anxiety producing drugs have the opposite
effect.The expression of scores as percentage of time and distance in open arms allows
for the correction of overall changes due to exploration of the maze, reducing the
activity-induced artifacts (Hogg, 1996). Two factors are thought to represent anxiety in
the EPM: % open entries and % open time (Rodgers & Johnson, 1995). The EPM
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(Hamilton Kinder, model EPM2001, Poway, CA) consists of two open arms (2x14 in),
two closed arms (2x14 in), and a 2x2 in central square. The entire maze is raised 30
inches above the floor. One week after injections, the mice were moved to the dark
testing room and left to acclimate for 45 minutes prior to the test. Testing was performed
in the morning and in the dark to account for possible influences by light level and
circadian rhythm on the anxiolytic behavior (Walf & Frye, 2007). For the test, mice were
placed in the central square facing an open arm and left to explore for 5 minutes.
Between each trial, the maze was cleaned using 70% ethanol and dried. Automated
software (Kinder Scientific MotorMonitor Software Package, Build 08356-14 Update
12jan2008) kept a record of the number of entries, distance traveled (inches), and time
spent (seconds) in the closed and open arms. Entry was determined when all four paws of
the mouse were on the arm. Scores were transformed to percents in open arms. An
increase in time and entries into open arms compared indicate an anxiolytic effect.
Cholinesterase activity
Frontal cortex (FC) tissue was dissected to determine cholinesterase activity in the
mice 14 days post-injection. The FC tissue was sonicated for 5 seconds 2-3 times in 200
µL of 0.1 M NaPO4 pH 7.4 buffer with 0.5% Tween-20. Following sonication, the
samples were centrifuged at 13000 rpm for 5 minutes at 4° C. Two 0.5 mL microtubes
were prepared for each sample: one for inhibited and one for uninhibited. The inhibited
tube received 1 µL of 10mM iso-OMPA (tetraisopropyl-pyrophosphoramide). After
centrifugation, 99 µL of supernatant was transferred to each 0.5 mL microtube, gently
mixed, and left on ice for 45 minutes to allow for inhibition of butyrylcholinesterase
(BuChE) activity. During the inhibition process, a 96 well plate was prepared. Each
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sample was done in triplicate, resulting in 3 wells for uninhibited and 3 for inhibited. In
the wells, 150 µL of 0.1 M NaPO4, pH 8.0, 10 µL of each sample, 20 µL of 0.01M
DTNB (dithionitrobenzoate made in 0.1M NaPO4 buffer, pH 7.0), and 20 µL of 0.01M
ATCh (acetylthiocholine made in DDI). Cholinesterase activity was determined using a
BiotekTM EL808 Microplate Analyzer and Gen5 software (version 1.02.8). Protein
concentration was determined from the supernatant using the Bradford method (BioRad,
Inc). BuChE activity was calculated by subtracting the AChE activity from the total ChE
activity and was reported as nmol/µg tissue/ min.
Neuropathology
Histology
Mice were lightly anesthetized via CO2 and decapitated. Whole brains were
removed and flash frozen using isopentane prior to storage in the -80° C freezer. Slides
were cleaned and gelatin coated prior to use following a standard method in which they
were soaked in gelatin for a few minutes, drained on a paper towel, and dried in an oven
at 60°C for 2 hours and placed in slide boxes until use. Brains were sectioned 12 microns
thick using the Cryotome (Thermo Shandon, model 77210163GB). Brains were attached
to the sectioning block with tissue freezing medium (TBS, INC, Durham, NC). Sections
were collected between 0.64 mm and 1.98 mm (Franklin & Paxinos, 2008). Four sections
were placed on each slide and 15-20 slides were collected from each brain. Slides were
then left out at room temperature overnight to dry. The next day, the slides were postfixed in 4% Paraformaldehyde, diluted from 16% PFA (EMS, lot: 110720) using PBS
(pH 7.2), for 10 minutes. Following post-fixation, the slides were rinsed twice for two
minutes with PBS and then placed on a slide warmer set to 37 ° C for 30 minutes. The
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slides were left at room temperature for 4 hours prior to being placed in the -20 freezer
for storage until staining was performed.
Pictures of the stained slides were taken using a Leica DMR microscope and the
Leica DFC 310 FX camera. Leica Application Suite (version 3.7.0) was used to save the
pictures. The regions analyzed consisted of amygdala, dentate gyrus of the hippocampus,
and the piriform cortex. Pictures were analyzed using Image J (NIH, version 1.44) for
area and cell counts.
GFAP staining
Glial cells are activated in response to neural injury. Changes in the glial cells,
such as astrogliosis and hypertrophy, are associated with increases in glial fibrillary
protein (GFAP). An increase of GFAP indicates activated astrocytes at the site of injury.
Microglia are the primary immune effector cells of the CNS and undergo changes after
brain injury. Seizures cause reactive changes in astrocytes and microglia. After soman
exposure, an increase in GFAP staining was observed in anatomically specific sites, such
as the piriform cortex and the hippocampus (Zimmer, Ennis, & Shipley, 1997). A sharp
peak of microgliosis occurred 3 days post-exposure. Between post-exposure day 8 and
day 15, a pattern of over-expression of GFAP was seen in the hippocampus and
amygdala and is most likely due to gliosis (Collombet et al., 2005).
Prior to staining, the slides were allowed to warm to room temperature. An
antigen retrieval process was required due to the formaldehyde cross-links. Slides were
placed in a tris-EDTA buffer, pH 9.0, heated to 70-75° C for 20 minutes and then left out
to cool for 20 minutes. The sections were marked with a Pap pen (RPI). The slides were
then placed in a humidity chamber for the remaining of the staining process. Slides were
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washed with 0.01M PBS + 0.1% Triton X (PBS-T) 3 times for 5 minutes. Blocking was
done using 10% Normal Goat Serum for 30 minutes. The slides were rinsed with PBS-T
for 2 times for 5 minutes. The GFAP primary antibody (Invitrogen rabbit x anti-GFAP)
was diluted to a 1:500 concentration in PBS-T. The primary antibody was left on the
slides overnight at 4° C. Another wash step using PBS-T was done (3 times for 5
minutes). The secondary antibody, anti-rabbit IG Fluoroscein linked whole antibody from
donkey (GE healthcare), a 1:50 concentration, was left on the slides for 2.5 hours. A rinse
step was completed with PBS (3 times for 5 minutes) prior to coverslipping. The
coverslip was mounted using mounting medium for fluorescence (Vecta-shield, H-1400
and H-1000).
NeuN staining
When exposed to soman, damaged neurons were deprived of the
immunoreactivity for Neuronal nuclei (NeuN). NeuN stains neuronal cells which are
post-mitotic and morphologically differentiated (Mullen, Buck, & Smith, 1992). NeuN
protein levels were not affected, so the loss of immunoreactivity was suggested to be due
to reduced antigenicity of the degenerating neurons (Collombet et al., 2006). In the
hippocampus, NeuN-positive cells peaked at day 1 and remained unchanged until day 15.
The number of positive cells decreased after soman exposure by 40% in the first week
(Collombet et al., 2006).
Slides were stained using the same method as for GFAP. The NeuN primary
antibody (Millipore MAB377 mouse anti-NeuN clone A60) was diluted to a
concentration of 1:100 using PBS-T. The secondary antibody (anti-mouse cy-3 from
goal, Jackson labs) was made to a 1:1000 concentration.
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Statistical Analysis
Statistical analysis was performed using Statistica (Statsoft, version 7). Weight
loss data were analyzed using a repeated measures ANOVA with a Fisher LSD post-hoc
test. FOB data were analyzed with a Kruskal-Wallis ANOVA with multiple comparison
post-hoc test. Histology, open field, elevated plus maze, and AChE data were analyzed
using a one-way ANOVA with a Tukey or Fisher LSD post-hoc test, based on the best
test for the data.
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IV. Results
Mortality and Seizure data
Seizure latency data and death latency data were recorded for each animal and
analyzed using a one-way ANOVA with a Tukey post-hoc test. The average latency to
the first seizure (F5,82=10.33, p<0.001) increased from 7minutes 54 seconds in the
positive controls (sarin treated) to 16 minutes 36 seconds at the 0.1 mg/kg dose CM2,525 (p<0.01) with other doses in between (see table 1). Treatment with DPAT did not
have an effect on latency to seizure or latency to death. The average latency to death
(F3,18=5.05, p<0.05) in CM-2,525-treated groups was similar to that of the positive
controls (sarin treated) except at the 1 mg/kg dose of CM-2,525 for which it increased
(p<0.05). Three groups contained animals that did not exhibit seizure activity: four out of
14 (28.6%) in the 0.1 mg/kg dose and one animal (10%) in the 0.03 mg/kg CM-2,525
group, and one animal (5.6%) in the DPAT group. All animals in the positive controls
and all other doses of CM-2,525 exhibited seizure activity. In summary, the 0.1 mg/kg
dose had a beneficial effect on the average time to the first seizure. Both the 0.1 mg/kg
and 0.03 mg/kg doses of CM-2,525 had animals that did not display seizure activity. The
1 mg/kg dose of CM-2,525 increased the latency to death compared to the positive
controls. A beneficial effect with regards to seizure latency and latency to death was not
seen in animals given 1 mg/kg DPAT.
The percent mortality at three days was lowest in the DPAT (33.3%) and 0.1
mg/kg of CM-2,525 (28.6%) but highest after 1 mg/kg of CM-2,525 (70%). The 0.03

26
	
  

	
  
	
  

mg/kg and 0.31 mg/kg doses of CM-2,525 were similar to the positive controls. In
summary the DPAT group and the 0.1 mg/kg dose of CM-2,525 showed a decrease in
percent mortality
Table 1: Average latency to seizure and death (minutes: seconds) of those responding and
percent mortality for CM-2,525 and DPAT.
Group
Latency Latency %
%
%
%
%
to
to death never
mortality mortality mortality mortality
seizure
seized same day 1 day
3 days
4 days
Positive
Controls
1 mg/kg
DPAT
0.03
mg/kg
525
0.1
mg/kg
525
0.3
mg/kg
525
1 mg/kg
525

7:54

16:35

0

30

30

49

55

7:58

17:48

5

33

33

33

33

6:30

10:50

10

40

40

40

50

16:36

14:17

29

7

14

29

29

11:22

13:27

0

10

20

40

40

7:15

24:59

0

40

50

70

70

Functional Observational Battery (FOB)
A Kruskal-Wallis ANOVA indicated differences at one hour (H5=0.001), two
hours (H5<0.001), and 24 hours (H5<0.05) (see figure 3). The positive controls, 0.3
mg/kg and 1 mg/kg CM-2,525, and 1 mg/kg DPAT showed a similar pattern of high
scores at one hour to slightly lower scores by 24 hours. The 0.03 mg/kg dose CM-2,525
had lower scores at every time point and was significant at 24 hours (p<0.01). The 0.1
mg/kg group had lower scores at one and two hours (p<0.01). The 0.3 mg/kg CM-2,525
group had slightly higher scores at every time point than the positive controls, though
none were significant. DPAT and 1 mg/kg CM-2,525 had no effect on FOB scores. Thus
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the lower doses of CM-2,525 produced some reduction in symptoms at every time point
except four hours.

Figure 3: FOB scores for varying doses of CM-2,525 compared to DPAT. * indicates
differences from positive controls, p<0.05.
Weight loss
Weight loss at one day is mainly due to immobility and dehydration. A decrease
by 20% or more on day three correlates with severe impairment. The results were
significant at both one day (F5,31=11.03, p<0.001) and at three days (F5,31=11.41,
p<0.001) (see figure 4). There was an increase in weight loss in the 0.03 mg/kg group at
day one and at day three (p<0.05). There was a decrease in weight loss in the 0.1 mg/kg
group at day one (p<0.05) but not at day three. There was a clear protection from weight
loss in the 1 mg/kg group at day one (p<0.001) and an increase in body weight by day
three (p<0.01). DPAT had no effect on weight either day. In summary, the 1 mg/kg dose
of CM-2,525 reduced loss in body weight to the extent that they were no different from
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negative controls whereas the 0.03 mg/kg dose produced an increase in weight loss at
both days compared to the positive controls.

Figure 4: Percent weight loss for varying doses of CM-2,525 given one minute after sarin
and 1 mg/kg DPAT. * indicates differences from positive controls day 1, # indicates
differences from positive controls day 3, p<0.05.
Behavior
Behavior tests were only performed using positive controls, DPAT, and the 0.03
mg/kg dose of CM-2,525; this was due to the Army, ICD, declining to ship additional
sarin and the consequential loss of funding and access to active agent. Historic controls
were utilized for negative controls and for DPAT in the elevated plus maze due to lack of
animals. The historic data used are a representation of results consistently found at
similar time points in the laboratory.
Open Field (OF)
The OF analyzes general locomotor activity and willingness to explore. Mice
were tested two days after sarin exposure. A one-way ANOVA showed differences in
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peripheral distance (F3,16=4.12, p<0.05), peripheral rest time (F3,16=3.67, p<0.05), basic
movements (F3,16=7.23, p<0.01), and fine movements (F3,16=3.45, p<0.04).
Periphery distance and basic movements have a similar pattern suggesting fewer
movements with the positive controls and DPAT compared to the negative controls
(p<0.05). The 0.03 mg/kg CM-2,525 dose was similar to the negative controls with basic
movements and periphery distance (see figure 5A and 5C). Periphery rest time increased
for DPAT compared to the negative control (p<0.05). The 0.03 mg/kg CM-2,525
periphery rest time was similar to the negative control (see figure 5B). Fine movements,
such as grooming, decreased in the DPAT animals compared to the negative control
(p<0.05) (see figure 5D). In all cases, the 0.03 mg/kg CM-2,525 group was similar to the
negative controls. No differences were seen with center time and distance or rearing. In
all measures, the 0.03 mg/kg CM-2,525 group was not different from the negative
controls and DPAT treatment resulted in scores much like the positive controls.
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Figure 5: Differences in OF, a comparison of 1 mg/kg DPAT to 0.03 mg/kg CM-2,525 to
the positive controls in (A.) periphery distance, (B.) periphery rest time, (C.) basic
movements, and (D.) fine movements. * indicates differences from the negative controls,
p<0.05. OF was performed 2 days after exposure.
Elevated Plus Maze (EPM)
The EPM was used to monitor the anxiolytic properties of CM-2,525 and DPAT
and was performed seven days after sarin exposure and treatment. Historic controls were
added to DPAT, by 7 days only one animal was still alive in the group. An ANOVA
revealed differences in percent open arm distance (F4,15=4.67, p<0.05), percent total time
in open arms (F4,15=6.11, p<0.01), and percent rest time in open arms (F4,15=9.95,
p<0.001). Differences were also seen in basic movements, which parallels what was seen
in the open field, with 0.03 mg/kg CM-2,525 resulting in a score similar to the negative
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control. The 0.03 mg/kg CM-2,525 group had increases in time in the open arms, rest
time in the open arms, and distance in open arms compared to both controls (p<0.05) (see
figure 6). DPAT was similar to the controls in distance and total time in the open arms,
and was slightly decreased though not significant in percent rest time in the open arms.
The increase in total body movements combined with the increase in open arm time for
the 0.03 mg/kg CM-2,525 group is indicative of a greater tolerance of a stressful event
than either positive or negative controls.

Figure 6: Differences in EPM for 1 mg/kg DPAT and 0.03 mg/kg CM-2,525 against the
positive controls for (A). % distance in open arms, (B.) % total time in open arms, and
(C.) % open arm rest time. * indicates p<0.05 compared to controls. EPM was performed
7 days post-exposure.
Cholinesterase (ChE) activity
Animals were lightly anesthetized via CO2 and decapitated at 14 days; frontal
cortex tissue was dissected and used for the AChE assay. Frontal cortex tissue for the
lowest dose of CM-2,525 was not collected and thus was not included in the study.
Results were analyzed using a one-way ANOVA with a Tukey post-hoc test. Historic
controls were added for negative controls for a better comparison. Differences were seen
with AChE (F5,25=6.90, p<0.001). The positive controls had lower levels than the

32
	
  

	
  
	
  

negative controls (p<0.01). DPAT and the lower doses of CM-2,525 restored the levels
back towards the negative controls (see figure 7). The highest dose of CM-2,525
produced a decrease in levels of AChE compared to the negative controls (p<0.001) and
was not different from the positive controls.

Figure 7: AChE rates (nmole/min/µg protein) for varying doses of 525 compared to
DPAT and controls. * indicates differences from negative controls, p<0.05.
Neuropathology
Brain sections were stained for Glial Fibrillary Acidic Protein, GFAP, which
increases after sarin exposure, and Neuronal Nuclei, (NeuN), which decreases after sarin
exposure. Staining with GFAP and NeuN revealed differences in the amygdala, dentate
gyrus, and the piriform cortex regions. A one-way ANOVA followed by a Tukey posthoc test was performed to detect differences.
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Figure 8: (A.) GFAP staining and (B.) NeuN staining in the dentate gyrus for varying
doses of CM-2,525 compared to DPAT and negative and positive controls. * indicates
differences from negative controls and # indicates differences from positive controls,
p<0.05.
Differences in GFAP and NeuN staining were seen in the dentate gyrus
(F6,36=28.25, p<0.001) (F6,24=6.62, p<0.01) (see figure 8). The higher doses of CM-2,525
resulted in similar levels of GFAP staining to the negative control and was reduced
compared to the positive controls (p<0.01). The DPAT group had an intermediate
response with a slight decrease, but was not significant from either controls (see figure
8a). The 0.03 mg/kg CM-2,525 group was increased beyond the positive control
(p<0.001). NeuN staining followed a similar pattern as GFAP staining with the higher
doses of CM-2,525 resulting in similar NeuN levels as the negative controls. The 0.1
mg/kg and 1 mg/kg CM-2,525 groups were not different from the negative controls.
DPAT and 0.3 mg/kg CM-2,525 had an intermediate effect with levels increased
compared to the positive controls, but was not different from either controls (see figure
8b). A decrease in NeuN staining compared to the negative controls was observed in the
0.03 mg/kg CM-2,525 and was similar to the positive controls (p<0.05). Thus in the
dentate gyrus the higher doses of CM-2,525 provided nearly complete protection.

34
	
  

	
  
	
  

Figure 9: GFAP staining in the dentate gyrus for (A.) no primary added control, (B.)
negative control, (C.) positive control, (D.) DPAT, (E.) 0.03 mg/kg 525, (F.) 0.1 mg/kg
525, (G.) 0.3 mg/kg 525, and (H.) 1 mg/kg 525.

Figure 10: NeuN staining in the dentate gyrus for (A.) no primary added control, (B.)
negative control, (C.) positive control, (D.) DPAT, (E.) 0.03 mg/kg 525, (F.) 0.1 mg/kg
525, (G.) 0.3 mg/kg 525, and (H.) 1 mg/kg 525.
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Figure 11: GFAP and NeuN overlay of the dentate gyrus for (A.) no primary added
control, (B.) negative control, (C.) positive control, (D.) DPAT, (E.) 0.03 mg/kg 525, (F.)
0.1 mg/kg 525, (G.) 0.3 mg/kg 525, and (H.) 1 mg/kg 525.

Figure 12: (A.) GFAP staining and (B.) NeuN staining in the amygdala for varying doses
of CM-2,525 compared to DPAT and negative and positive controls. * indicates
differences from negative controls and # indicates differences from positive controls,
p<0.05.
In the amygdala, the higher doses of CM-2,525 (p<0.01) produced GFAP levels
(F6,33= 13.27, p<0.001) similar to negative controls. DPAT showed a trend towards a
reduction in GFAP staining, but was not significant. The 0.03 mg/kg dose CM-2,525
produced an increase in GFAP staining compared to negative controls (p<0.001) and was
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similar to the positive controls (see figure 12a). NeuN staining was increased but was not
different from either positive or negative controls at doses above 0.1 mg/kg of CM-2,525
and DPAT was increased significantly above the levels of the positive controls (see
figure 12b). The 0.03 mg/kg dose CM-2,525 produced a decrease in NeuN staining
similar to the positive control. Based on the results of GFAP staining and NeuN, the 0.1
mg/kg CM-2,525 dose provided the best protection in the amygdala followed by DPAT.

Figure 13: GFAP staining in the amygdala for (A.) no primary added control, (B.)
negative control, (C.) positive control, (D.) DPAT, (E.) 0.03 mg/kg 525, (F.) 0.1 mg/kg
525, (G.) 0.3 mg/kg 525, and (H.) 1 mg/kg 525.

Figure 14: NeuN staining in the amygdala for (A.) no primary added control, (B.)
negative control, (C.) positive control, (D.) DPAT, (E.) 0.03 mg/kg 525, (F.) 0.1 mg/kg
525, (G.) 0.3 mg/kg 525, and (H.) 1 mg/kg 525.
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Figure 15: (A.) GFAP staining and (B.) NeuN staining in the piriform cortex for varying
doses of CM-2,525 compared to DPAT and negative and positive controls. * indicates
differences from negative controls and # indicates differences from positive controls,
p<0.05.
GFAP staining in the piriform cortex did not result in differences between the
negative controls (untreated animals) and the positive controls (see figure 15a), although
differences were seen with 0.03 mg/kg dose of CM-2,525 and DPAT (F6,34=9.75,
p<0.001). Increases in GFAP staining compared to both controls were observed with
DPAT and 0.03 mg/kg CM-2,525 (p<0.05). When stained with NeuN (F6,23=5.64,
p<0.01), a decrease in staining was seen in the positive controls (p<0.001) and the 0.03
mg/kg dose (p<0.05). The higher doses of CM-2,525 resulted in intermediate NeuN
staining compared to the controls (see figure 15b). Treatment with DPAT increased
NeuN staining compared to the positive controls (p<0.01) and was not different from the
negative controls. In the piriform cortex, the higher doses of CM-2,525 produced a slight
protection from sarin exposure based an increase in NeuN staining. DPAT produced an
increase in GFAP staining and near complete protection based on the increase in NeuN
staining.

38
	
  

	
  
	
  

Discussion
This study determined that CM-2,525 is more efficacious than 8-OH-DPAT in
providing neuroprotection in a dose-dependent manner. The middle doses of CM-2,525
were efficacious against the acute toxicity, including mortality, FOB, and AChE levels.
The higher doses were efficacious against the neurotoxicity measures such as weight loss
and histochemical markers. Neuroprotection was observed in the dentate gyrus and
amygdala as measured both by a reduction in glial fibrillary protein, GFAP, staining for
astrocytes as a measure of neuronal damage and by denser NeuN staining for mature
neurons. Treatment with 8-OH-DPAT had effects on percent mortality, but not FOB or
weight loss. Previously, DPAT was effective when given two hours after sarin at
reducing the neural injury in the dentate gyrus. As a comparison with CM-2,525, DPAT
was effective at providing neuroprotection in the amygdala and dentate gyrus when given
one minute after sarin. Low doses of CM-2,525 were better than DPAT on FOB and the
intermediate doses were better than DPAT on weight loss and immunohistochemistry
measures.
Use of CBDP and sarin
In our animal model, we use CBDP and the active agent sarin. CBDP, the
carboxylesterase inhibitor 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorin-2- oxide,
catalyzes the hydrolysis of carboxylesters (Wheelock et al., 2008). Carboxylesterase is
another enzyme with sarin as a substrate and acts as a scavenger to reduce the amount of
administered sarin available for binding to acetylcholinesterase (AChE). Rats and mice
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express a larger amount of carboxylesterases (CaE) than humans so it is important to
lower its levels. With reduced levels of sarin, less non-specific effects from the hydrogen
flouride leaving group are seen. By reducing the levels of CaE in the mouse, it becomes
possible to use a lower dose of sarin to achieve an LD50 much closer to that of other
species. The dose of CBDP chosen, 1.5 mg/kg, does not inhibit AChE activity in the
brain or blood of mice when used alone (Garrett et al., 2010).
The use of sarin instead of surrogates was necessary for this study. The
organophosphate pesticides and surrogate agents have different characteristics than the
nerve agents, despite being cholinesterase inhibitors. Nerve agents are 100-1000 times
more potent than the pesticides. The differences in toxicity are due to the chemical
groups surrounding the phosphorus atom (Forsberg, 1995). Though the biological effects
are similar between the pesticides and nerve agents, differences exist in duration of
biological activity and response to therapy (U.S.Army Medical Research Institute of
Chemical Defense, 2007). Nerve agents have shorter durations of biological effects and
respond faster to therapy, whereas the pesticides have a longer duration and can have
delayed onset of symptoms (Sidell, 1994; Keyes, 2005). As for treatment, larger amounts
of atropine are needed to treat severe pesticide poisoning. There are two main reasons for
differences in biological activity. The pesticides have a greater fat solubility than nerve
agents and may be sequestered in the fat stores providing a longer duration of free levels
(Sidell et al., 2008). Differences may also be due to the ability of the pesticide
compounds to bind with the target enzyme, AChE, and the rate of ACh accumulation
(Savolainen, 2001). Nerve agents bind irreversibly to the target enzymes and have a
longer duration of action. These differences and possible unknown differences between
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pesticides and nerve agents support the use of active agent for studying nerve agent
treatments. The FDA, for drug approval using the animal rule, also necessitates the use of
active agent. In order to get a new drug approved when human studies are not ethical and
feasible, the challenge agent used in the animal studies must be identical to the agent
causing human disease (Food and Drug Administration, 2009).
It is also important to note that differences between kainic acid and sarin were
found with the C57BL/6 mouse strain. Based on several measures including dose, AChE
levels, weight loss, and histological measures, it was determined that the C57BL/6 mouse
strain was sensitive to sarin. Studies with kainic acid, a glutamatergic agonist, revealed
the C57BL/6 mouse strain was resistant to seizures and to the consequential neuronal
damage (McLin & Steward, 2006). The levels of AChE inhibition and time course for
toxicity were different after DFP, an organophosphate pesticide, though the same strain
was found sensitive. AChE levels were inhibited for 24 hours and then began to rise
again (Smolen, Smolen, Wehner, & Collins, 1985). Levels of AChE stay inhibited after
sarin exposure for at least 14 days (Garrett et al., 2010). Such differences between the
possible surrogates and active agent neurotoxicity support the need for the use of active
agent in novel therapeutic research.
Dose-response of CM-2,525
A dose-response curve from 0.03 to 1.0 mg/kg one minute after toxic challenge
was completed to assess the efficacy of CM-2,525 against sarin. CM-2,525 was effective
at reducing mortality and improving the latency to seizure. The dose of 0.03 mg/kg also
had a proportion of animals that did not seize but had little effect on latency to seizure or
mortality. The dose of 0.1 mg/kg CM-2,525 produced an enhancement in mortality. The
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latency to seizure increased by nearly double that of the positive controls and an
appreciable percentage of animals did not seize at the intermediate doses. The higher
doses of CM-2,525 had little effect on mortality or latency to seizure. Based on mortality
and seizure latency, the 0.1 mg/kg dose CM-2,525 had the best results. Sarin-induced
seizures are initiated by the cholinergic system, due to the accumulation of acetylcholine
(ACh) in the central nervous system. The seizures are thought to be maintained by a
mixture of cholinergic and noncholinergic components, mostly glutamate (Tang, Loke, &
Ling, 2011). The release of glutamate into the extracellular matrix induces neuronal
swelling and death due to calcium influx followed by water into the neuron. The current
hypothesis regarding nerve agent induced-excitotoxicity states that glutamate release
activates both NMDA and non-NMDA glutamatergic receptors leading to neuronal death
(Solberg & Belkin, 1997). Delayed latency to seizure and the increase in survival with
CM-2,525 points toward a protective effect and a disruption of the excitotoxic state
brought on by sarin exposure at the earlier time points.
A Functional Observational Battery was used to assess acute toxicity and detect
differences in neurobehavioral parameters. FOB scores were decreased with the lower
doses of CM-2,525 signifying a reduction in acute symptomology. The higher doses had
no effect on FOB scores. The FOB is a valid test for detecting acute toxicity and is
commonly used for neurotoxicity screening. By defining relevant categories representing
the different biological actions of the toxic compound, the FOB allows for the sampling
of behavioral and neurological functions in the animal model and a comparison to
humans (Moser, 1990).
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Acetylcholinesterase activity was analyzed using frontal cortex tissue 14 days
post-exposure. Sarin decreased AChE activity at this time point. A reduction was
observed in the positive, sarin treated, controls compared to the negative controls. The
inhibition seen in the positive controls demonstrates that sarin was effective. The lower
doses of CM-2,525 increased AChE activity and produced levels slightly below the
negative controls. Treatment with 1 mg/kg CM-2,525 did not protect AChE as the value
was similar to the positive controls. The lower doses of CM-2,525 had a protective effect
on the AChE levels in the frontal cortex resulting in levels not different from either
negative or positive controls. Blood AChE levels are restored quickly, by day 4, from
replacement of red blood cells (Garrett et al., 2010). AChE levels in the brain take longer
to restore because new enzyme must be synthesized. Studies with soman revealed a
correlation between moderate to severe symptoms and a strong ChE inhibition in the
brain 24-48 hours after exposure. A complete recovery of AChE levels in the brain did
not occur by day 8 (Lemercier et al., 1983) and inhibition of AChE was seen in the
frontal cortex up to 14 days post-exposure with sarin (Garrett et al., 2010). The apparent
protection of low doses of CM-2,525 was not seen with the higher doses. This pattern of
differences with AChE in the dose-response of CM-2,525 is similar to that seen with
FOB scores in that the lower doses are effective but not the higher doses. This
correspondence is sufficient explanation for the ability of only low doses to reverse the
acute behavioral effects since the high doses did not have an effect on FOB scores.
Weight loss over three days was found to correlate with severe neuropathology
after soman exposure; the threshold for severe impairment was determined to be 20%
decrease in weight by the third day (Filliat et al., 2007). Changes in body weight were
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observed on both days 1 and 3 after sarin treatment. The lower doses of CM-2,525
reduced the amount of weight lost and the higher dose actually resulted in a weight gain.
Based on FOB scores, the 0.1 mg/kg dose of CM-2,525 had the best results, but had only
a slight effect on weight loss. The 1 mg/kg dose resulted in improvements in body
weight, but had no effect on FOB scores. A similar finding was seen after sarin exposure
with weight loss most pronounced during the first three days (Kadar et al., 1995). A
positive correlation was also found between weight loss and latency to onset of somaninduced seizures, similar to what is observed in studies with epilepsy (Myhrer, Enger, &
Aas, 2007). The reduction in symptoms with the lower doses of CM-2,525 was expected
based on the increase in latency to seizures. Differences in the dose-response curves
between FOB and weight loss may provide insight into how and where CM-2,525 is
acting and could lead to new insights into the sequence of events leading to neurotoxicity.
Two behavioral tests were completed to compare general locomotor activity,
willingness to explore, and the anxiolytic/anxiogenic properties of CM-2,525. Only a
limited number of groups were tested due to lack of funds. The open field test was
completed two days after sarin treatment. A slight decrease in distance and an increase in
rest time were observed, though the overall locomotor activity was not different among
the groups. Differences in the peripheral distance and rest time were not observed
between the sarin treated animals and the controls. Treatment with CM-2,525 brought the
basic movements, fine movements, and periphery distance and rest time values to those
seen in the negative controls, reversing the differences seen with sarin treatment. The
cholinergic system is thought to play a role in regulating locomotor activity. A reduction
in general locomotor activity is likely a symptom of the overstimulation of the

44
	
  

	
  
	
  

cholinergic system (Mach et al., 2008). Differences in locomotor activity were found
after exposure to sarin and soman in rodents. Soman exposed guinea pigs had lower
exploratory behavior than controls three months after the initial exposure (Mamczarz,
Pereira, Aracava, Adler, & Albuquerque, 2010b; Mamczarz, Pereira, Aracava, Adler, &
Albuquerque, 2010a). Repeated low doses of sarin resulted in less activity and a
reduction in basic movements and exploratory activity one day post-exposure (Mach et
al., 2008). Higher doses of sarin increased immobility and decreased fine movements,
grooming, and basic movements, rearing up to 6 hours after injection, however the
differences were not present from 6 to 72 hours between the sarin treated animals and
controls (Nieminen, Lecklin, Heikkinen, & Ylitalo, 1990). In this study, sarin treated
animals did not have a reduction in overall locomotor behavior 48 hours after treatment,
but did have deficits in basic and fine movements that were reversed by CM-2,525 This
result indicates that the acute treatment prevented the lasting effects of the toxic
challenge because the countermeasure was cleared from the system before the behavioral
tests were conducted.
The elevated plus-maze was used to measure the anxiolytic/anxiogenic response
one week after treatment. Anxiolytic responses are indicated by increases in percent open
arm time and distance (Hogg, 1996). Seven days post sarin exposure there were no
differences from the negative controls. CM-2,525 treatment, combined with the toxic
challenge, increased the total distance, total time, and rest time in the open arms
compared to both the negative and positive, sarin treated, controls. This is indicative of
an anxiolytic response and a greater tolerance of a stressful environment. Studies with
soman have found no differences in elevated plus-maze seven days after soman but
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decreased open arm time and open arm entries 30-60 days post-exposure, suggesting a
delayed onset anxiogenic effect after both high and low doses (Baille et al., 2001;
Coubard et al., 2008). The lack of differences between the sarin-treated controls and the
negative controls is similar to what was found after soman treatment. The effect from
CM-2,525 is likely not a direct effect from treatment as the drug had left the system prior
to testing. The increases with CM-2,525 treatment after the toxic challenge may represent
an interaction with the drug and sarin resulting in a behavioral change.
CM-2,525 as a neuroprotectant
Sarin-induced neurotoxicity is due to the seizure activity which rapidly progresses
to status epilepticus. Seizures begin after an overstimulation of the muscarinic ACh
receptors leading to calcium-sensitive non-specific cation current and the release of
glutamate. The excitotoxic neuronal damage is due to the glutamatergic hyperactivity and
the resulting sustained and reinforced seizure activity. A strong correlation exists between
seizure intensity and duration and the severity of the neuropathology (AroniadouAnderjaska, Figueiredo, Apland, Qashu, & Braga, 2009). Seizure induction is thought to
start in the piriform cortex and spread to the amygdala and hippocampus as profound
damage is seen in these areas after nerve agent exposure (Tattersall, 2009; AroniadouAnderjaska et al., 2009). The hippocampal region appears to be activated before the
amygdala in the excitiotoxic response (Myhrer et al., 2007). The innervated areas
affected by nerve agent exposure have both muscarinic and nicotinic ACh receptors.
Damage increased in severity one week after exposure compared to 24 hours in rats.
There was a loss of neurons in the piriform cortex and amygdala and gliosis in the
hippocampus. No further decline in damage was seen from one week to three months
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(Kadar et al., 1995). Since damage mainly occurs in the dentate gyrus of the
hippocampus, piriform cortex, and amygdala, these areas were examined for
neuropathology.
Glial fibrillary acidic protein (GFAP) is a marker for astrocyte activity reflecting
neuronal damage and stress and it increases after sarin exposure. GFAP staining
increased in the dentate gyrus of the hippocampus after exposure 1 day post-exposure and
was evident until day 15. The peak was evident at day 14 after sarin exposure (Garrett et
al., 2010). An increase in astrocytic GFAP indicates neural trauma or injury and without
the use of another stain or measure, a drug-induced decrease in sarin treated animals does
not necessarily suggest neuroprotection (Collombet et al., 2007). As such, an additional
stain for mature, highly differentiated neurons, neuronal nuclei (NeuN) was included.
NeuN immunohistochemistry was found to be a good marker for predicting long-term
neuronal degeneration after soman exposure. The number of hippocampal neurons fell by
40 percent during the first week and continued to a 50 percent reduction by three months.
The number of NeuN-labeled cells in the hippocampus remained unchanged up to postsoman day 15 (Collombet et al., 2006). Using the time course of staining for GFAP and
NeuN after sarin and soman exposure, a time point of 14 days was chosen.
Immunohistochemistry was used to verify damage and determine the
effectiveness of CM-2,525 as a neuroprotectant. A decrease in GFAP and increase in
NeuN staining compared to the positive, sarin treated, controls signifies neuroprotection,
whereas an increase or constant GFAP value and a decreased NeuN signifies damage and
a lack of protection. Similar results were obtained in the amygdala and dentate gyrus
throughout. To verify prior work, DPAT treated animals were stained with GFAP and
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NeuN was added to confirm its efficacy. The 0.03 mg/kg dose of CM-2,525 increased
GFAP-positive cells and decreased NeuN-labeled cells and was similar to the positive
controls. This is in contrast to the decrease in FOB scores with the lowest dose. The
higher doses of CM-2,525 provided neuroprotection as demonstrated both by the
decrease in GFAP and by the increase in NeuN staining similar to the negative controls.
The 0.1 mg/kg and 1 mg/kg doses of CM-2,525 were the best at providing
neuroprotection in the dentate gyrus and the amygdala.
The piriform cortex had similar values for the GFAP staining in both positive and
negative controls at all doses except for 0.03 mg/kg in which it was increased. The
positive control had a reduction in NeuN-labeled cells and was similar to the 0.03 mg/kg
CM-2,525 group. The higher doses offered slight protection, as observed by the slight
increase in NeuN staining compared to the positive controls. However, in the piriform
cortex the amount of neuroprotection afforded by CM-2,525 was not as great as that seen
in the dentate gyrus and amygdala. Since the piriform is thought to be the initiator for
nerve agent-induced seizures it is possible that damage to the area, especially with
astrocytes, occurs early and is not present 14 days post-exposure; however, the damage,
as indicated by NeuN, still remains. After soman exposure, the amygdala was found to
have the most damage, followed by the hippocampus in terms of neurodegeneration. The
piriform was not as damaged at a longer time-course (Aroniadou-Anderjaska et al.,
2009). When looking at inflammation and apoptotic measures, the piriform showed an
increase in TUNEL staining for the first 4 hours after sarin and then diminished in
response (Davidson, 2007). The dentate gyrus had a prolonged increase at 10 days. By 14
days post-exposure, no differences were detected with IL-1β or TUNEL in the piriform

48
	
  

	
  
	
  

cortex. Differences were detected in the amygdala and dentate gyrus with IL-1β but only
in the dentate gyrus with TUNEL staining (Joshi, 2009). The GFAP response could have
receded by the 14 day time point used in this study. The reduction in NeuN staining of
the positive, sarin treated, controls suggests that damage did occur, though it wasn’t as
great as the damage that occurred in the amygdala and dentate gyrus.
Comparison with 8-OH DPAT
DPAT is a 5-HT1A receptor agonist and has previously been used in studies of
stroke, traumatic brain injury, and excitotoxicity models as a neuroprotectant (Oosterink,
Harkany, & Luiten, 2003; Berends et al., 2005). In models of excitotoxicity using
monosodium glutamate, DPAT was found to inhibit the depolarization-evoked release of
glutamate in the hippocampus (Kamei, Igarashi, & Kasuya, 1991). The use of 5-HT1A
receptor agonists resulted in a reduction in damage to neurons of 7-day old chick
embryos exposed to glutamate (Peruche et al., 1994).
Previously, a dose of 1 mg/kg DPAT was found efficacious when treatment was
delayed two hours after sarin exposure. A reduction in percent mortality and a decrease in
neural injury in the dentate gyrus, shown by the reduction in GFAP-positive astrocytes,
were observed with treatment from one minute to two hours post-exposure. DPAT had no
effect on weight loss or FOB scores. Protection of AChE levels was not seen with DPAT
at any time point (Joshi, 2009). The effects of DPAT were not prevented by a 5-HT1A
receptor antagonist, thus suggesting a role of an additional receptor, or secondary
pharmacology.
DPAT was used as a comparison with CM-2,525 because it was effective at
providing neuroprotection but its mechanism was not clear. As was found previously,
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treatment with DPAT one minute after sarin reduced the percent mortality and was
similar to the 0.1 mg/kg dose of CM-2,525. However, DPAT did not have an effect on
latency to seizure as did CM-2,525. While CM-2,525 had a positive effect on weight loss,
leading to weight gain with the highest dose, DPAT did not have an effect. In the open
field test, the DPAT group exhibited reduced periphery distance and increased time in the
periphery and reduced in basic and fine movements. This, taken with the increased time
and decreased distance traveled in the periphery, could be a sign of immobility. The
DPAT treated animals were similar to the positive controls while the CM-2,525 treated
animals were similar to the negative controls. Because the testing in this study occurred
two days after treatment, it is unlikely that the response was due to DPAT directly, as the
drug had been cleared from the system since the brain half-life of 1 mg/kg DPAT (SC) in
a rat is 26 minutes (Perry & Fuller, 1989). Compared to both controls in the elevated plus
maze, DPAT had no effect on percent distance, time, or rest time spent in the open arms.
Treatment with CM-2,525 in toxic-challenged mice produced increases in all
measurements consistent with a greater tolerance for a stressful environment. In this
study, DPAT treatment after sarin exposure had no effect and was similar in the elevated
plus maze to both positive and negative controls seven days post-exposure. These results
are consistent with an absence of effects seen in the control groups seven days after
soman exposure (Baille et al., 2001; Coubard et al., 2008). It is possible that an effect
would have been obtained at an earlier time point. The effect of CM-2,525 thus differed
from that of DPAT.
DPAT reversed the effects of the toxic challenge on AChE when given one
minute post-exposure. Two doses of CM-2,525 also were similar to the negative controls.
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Previously, DPAT one minute post-sarin produced AChE values that were similar to the
positive controls and were further inhibited at the longer time points (Joshi, 2009).
Although the effects on AChE in DPAT treated animals differed between the two studies
at one minute, the AChE values obtained for DPAT at one minute in both the present and
previous study were close. The differences in the two studies may be due to error alone
and as such the experiment should be repeated. However, the important point is that the
high doses of CM-2,525 that were neuroprotective, based on weight loss and
histochemistry measures, did not produce increases in AChE activity.
The previous study with DPAT treatment for sarin exposure only looked at the
dentate gyrus using GFAP, a stain for astrocytes. This study extends both the brain areas
and the markers for neuroprotection. In the amygdala, DPAT decreased GFAP staining
and increased NeuN staining to levels similar to the negative controls and provided
neuroprotection, though was as not great as that seen with the higher doses of CM-2,525.
Similar results were seen in the dentate gyrus, though the GFAP staining following
DPAT was intermediate to the positive and negative controls and not significantly
different from either, as was the case in the previous study with DPAT. Neuroprotection
was afforded with DPAT, but the higher doses of CM-2,525 again had more of an effect.
Treatment with DPAT increased the amount of GFAP-positive cells in the piriform
cortex compared to both the positive and negative controls, but resulted in an increase in
NeuN-positive cells. This is a prime example that an increase in GFAP staining does not
necessarily indicate neuronal degeneration and only shows an injury has occurred.
Similar results of neuroprotection were observed 14 days post-ischemia. A reduction in
neuronal death and astroglial reaction was observed, suggesting increased neuronal
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survival in the DPAT treated animals (Ramos et al., 2004). Although DPAT is effective
as a neuroprotectant against sarin exposure, CM-2,525 afforded greater protection in the
amygdala and dentate gyrus one minute post-exposure as well as producing effects on
weight loss, FOB scores, and AChE levels.
Conclusions
When all the results are viewed together, CM-2,525 is more efficacious as a
neuroprotectant for sarin exposure than 8-OH DPAT. Not only does CM-2,525 offer
neuroprotection in the amygdala and dentate gyrus but also improves the percent
mortality, weight loss, and FOB scores. The mortality rate was further reduced by
treatment with CM-2,525 and an effect on latency to seizure and death was observed.
Weight loss and FOB scores were not reduced by DPAT but were by doses of CM-2,525.
Based on all the results, the 0.1 mg/kg dose of CM-2,525 was the best by offering the
lowest percent mortality, a reduction in FOB scores, less weight loss, and
neuroprotection.
The present results provide evidence of novel ways both of providing
neuroprotection and of understanding the physiological process that occur in response to
neurotoxic doses of nerve agents. There is an increase in serotonin turnover rate two
hours after sarin exposure (McDonough & Shih, 1997; Fernando, Hoskins, & Ho, 1984).
The changes in serotonin activity may represent an effort to restore homeostasis after
nerve agent seizures, an effect mimicked by DPAT at postsynaptic sites. Possible
secondary mechanisms for the neuroprotection afforded by the 5-HT1A agonists include
the inhibition of inflammation around blood vessels, the activation of G-protein coupled
potassium channels and the induced neuronal hyperpolarization, a reduction in glutamate
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release, and anti-apoptotic effects (Tfelt-Hansen, de Vries, & Saxena, 2000; Kline et al.,
2001; Adayev, El-Sherif, Barua, Penington, & Banerjee, 1999). CM-2,525 acts on the
part of the secondary pharmacology of DPAT that may underlie all of its beneficial
effects . The 5-HT1A receptor binding site is not crucial for neuroprotection because its
blockade does not prevent its actions. In fact, this component of the action of DPAT may
be counterproductive because of its action on 5-HT cell body autoreceptors to decrease
serotonin activity (Bonvento, Scatton, Claustre, & Rouquier, 1992). This component
would reduce activation of the relevant postsynaptic receptors by 5-HT, leaving only the
effects of DPAT to provide neuroprotection. CM-2,525 does not alter 5-HT neuronal
activity so that it’s postsynaptic effects would be additive to those of 5-HT. This could
explain its superiority over DPAT across the spectrum of measurements.
The other treatments currently used are only effective for up to 40 minutes postexposure and do not offer neuroprotection. Even experiments with ketamine and MK-801
did not offer neuroprotection past that time. New treatments being studied are mostly
effective only as pretreatments. Some work on glutamate and NMDA antagonists has
been done, but there are limitations in neuroprotection afforded (Weissman & Raveh,
2008). The effectiveness of DPAT and possibly of CM-2,525 at longer time points allows
for better treatment options for civilians and soldiers exposed to sarin. CM-2,525 and
DPAT do not act on the acute symptoms, so atropine and 2-PAM must still be used as
rescue-agents. However, CM-2,525 may be used in addition to the rescue agents for
treatment.
Future Studies
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Due to a change in management and vision at United States Army Medical
Research Institute of Chemical Defense (USAMRICD) access to the active agent was
terminated, making it impossible to complete the second aim, evaluating the timeresponse efficacy of CM-2,525 and comparison with 8-OH DPAT. As such, the work
done so far on CM-2,525 and DPAT is not complete. The time-course should be
completed. Additional work needs to be completed in order to gain an understanding into
the mechanism of DPAT and CM-2,525 against sarin exposure. A study using CM-2,525
at different time points after sarin exposure is necessary to further the comparison against
DPAT. The addition of the standard treatments, atropine and 2-PAM, with CM-2,525
would also be beneficial to explore.

54
	
  

	
  
	
  

References
Abou-Donia, M. B. (2003). Organophosphorus ester-induced chronic neurotoxicity. Archives of
Envirmental Health, 58(8), 484-497. Retrieved from ISI:000222322600005
Abu-Qare, A. W., & Abou-Donia, M. B. (2002). Sarin: health effects, metabolism, and methods
of analysis. Food and Chemical Toxicology, 40(10), 1327-1333. doi:doi: 10.1016/S02786915(02)00079-0. Retrieved from
http://www.sciencedirect.com/science/article/pii/S0278691502000790
Adayev, T., El-Sherif, Y., Barua, M., Penington, N. J., & Banerjee, P. (1999). Agonist
stimulation of the serotonin(1A) receptor causes suppression of anoxia-induced apoptosis
via mitogen-activated protein kinase in neuronal HN2-5 cells. Journal of Neurochemistry,
72(4), 1489-1496. Retrieved from ISI:000079204300020
Adayev, T., Ray, T., Sondhi, R., Sobocki, T., & Banerjee, P. (2003). The G protein-coupled 5HT1A receptor causes suppression of caspase-3 through MAPK and protein kinase C
alpha. Biochimica et Biophysica Acta-Molecular Cell Research, 1640(1), 85-96.
Retrieved from ISI:000182139900009
Alessandri, B., Tsuchida, E., & Bullock, R. M. (1999). The neuroprotective effect of a new
serotonin receptor agonist, BAY X3702, upon focal ischemic brain damage caused by
acute subdural hematoma in the rat. Brain Research, 845(2), 232-235. Retrieved from
ISI:00008339150001

55
	
  

	
  
	
  

Aroniadou-Anderjaska, V., Figueiredo, T. H., Apland, J. P., Qashu, F., & Braga, M. F. M.
(2009). Primary brain targets of nerve agents: The role of the amygdala in comparison to
the hippocampus. Neurotoxicology, 30(5), 772-776. Retrieved from
ISI:000271292900006
Baille, V., Dorandeu, F., Carpentier, P., Bizot, J. C., Filliat, P., Four, E. et al. (2001). Acute
exposure to a low or mild dose of soman: Biochemical, behavioral and histopathological
effects. Pharmacology Biochemistry and Behavior, 69(3-4), 561-569. Retrieved from
ISI:000170322600031
Bajgar, J., Fusek, J., Kassa, J., Kuca, K., & Jun, D. (2009). Chemical Aspects of
Pharmacological Prophylaxis Against Nerve Agent Poisoning. Current Medicinal
Chemistry, 16(23), 2977-2986. Retrieved from ISI:000268258700004
Ballough, G., Newmark, J., Levine, E., & Filbert, M. G. (2008). Neuroprotection as a treatment
for nerve agent survivors. In S. Tuorinsky (Ed.), Medical aspects of chemical warfare
(pp. 221-242). Washington, DC: US Dept of Army, Office of the Surgeon General,
Borden Institute.
Barnes, N. M., & Sharp, T. (1999). A review of central 5-HT receptors and their function.
Neuropharmacology, 38(8), 1083-1152. doi:S0028390899000106 [pii]. Retrieved from
PM:10462127
Berends, A. C., Luiten, P. G., & Nyakas, C. (2005). A review of the neuroprotective properties
of the 5-HT1A receptor agonist repinotan HCl (BAYx3702) in ischemic stroke.
CNS.Drug Rev., 11(4), 379-402. Retrieved from PM:16614737

56
	
  

	
  
	
  

Bonvento, G., Scatton, B., Claustre, Y., & Rouquier, L. (1992). Effect of local injection of 8OH-DPAT into the dorsal or median raphe nuclei on extracellular levels of serotonin in
serotonergic projection areas in the rat brain. Neuroscience Letters, 137(1), 101-104.
doi:doi: 10.1016/0304-3940(92)90308-T. Retrieved from
http://www.sciencedirect.com/science/article/pii/030439409290308T
Collombet, J. M., Carpentier, P., Baille, V., Four, E., Bernabe, D., Burckhart, M. F. et al. (2006).
Neuronal regeneration partially compensates the delayed neuronal cell death observed in
the hippocampal CA1 field of soman-poisoned mice. Neurotoxicology, 27(2), 201-209.
Retrieved from ISI:000235756500010
Collombet, J. M., Four, E., Bernabe, D., Masqueliez, C., Burckhart, M. F., Baille, V. et al.
(2005). Soman poisoning increases neural progenitor proliferation and induces long-term
glial activation in mouse brain. Toxicology, 208(3), 319-334. Retrieved from
ISI:000227112000001
Collombet, J. M., Four, E., Fauquette, W., Burckhart, M. F., Masqueliez, C., Bernabe, D. et al.
(2007). Soman poisoning induces delayed astrogliotic scar and angiogenesis in damaged
mouse brain areas. Neurotoxicology, 28(1), 38-48. Retrieved from ISI:000244844100006
Coubard, S. Béracochéa, D., Collombet, J. M., Philippin, J. N., Krazem, A., Liscia, P. et al.
(2008). Long-term consequences of soman poisoning in mice: Part 2. Emotional
behavior. Behavioural Brain Research, 191(1), 95-103. doi:doi:
10.1016/j.bbr.2008.03.027. Retrieved from
http://www.sciencedirect.com/science/article/pii/S0166432808001575

57
	
  

	
  
	
  

Davidson, M. E. (2007). Neurodegeneration and Neuroinflammation in a Mouse Model of Sarin
Exposure (, Wright State University). Retrieved from
http://rave.ohiolink.edu/etdc/view?acc_num=wright1189715827
Dorandeu, F., Carpentier, P., Baubichon, D., Four, E., Bernabe, D., Burckhart, M. F. et al.
(2005). Efficacy of the ketamine-atropine combination in the delayed treatment of
soman-induced status epilepticus. Brain Research, 1051(1-2), 164-175. Retrieved from
ISI:000231186800019
Dunn, M. A., & Sidell, F. R. (1989). Progress in Medical Defense Against Nerve Agents. JamaJournal of the American Medical Association, 262(5), 649-652. Retrieved from
ISI:A1989AG41200025
Fernando, J. C. R., Hoskins, B. H., & Ho, I. K. (1984). A Striatal Serotonergic Involvement in
the Behavioral-Effects of Anticholinesterase Organophosphates. European Journal of
Pharmacology, 98(1), 129-132. Retrieved from ISI:A1984SE31600017
Filliat, P., Coubard, S., Pierard, C., Liscia, P., Beracochea, D., Four, E. et al. (2007). Long-term
behavioral consequences of soman poisoning in mice. Neurotoxicology, 28(3), 508-519.
Retrieved from ISI:000247808700009
Food and Drug Administration. (2009). Guidance for Industry: Animal models - essential
elements to address efficacy under the animal rule. Retrieved from:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/ucm078923.pdf
Forsberg, R. (1995). Acquiring Weapons of Mass Destruction. In Nonproliferation Primer :
Preventing the Spread of Nuclear, Chemical, and Biological Weapons (pp. 39-61) MIT
Press.

58
	
  

	
  
	
  

Franklin, K. B. J., & Paxinos, G. (2008). The mouse brain in sterotaxic coordinates (3rd ed.).
New York, NY: Elsevier.
Garrett, T. L., Rapp, C. M., Grubbs, R. D., Schlager, J. J., & Lucot, J. B. (2010). A murine model
for sarin exposure using the carboxylesterase inhibitor CBDP. Neurotoxicology, 31(5),
502-508. doi:doi: 10.1016/j.neuro.2010.05.007. Retrieved from
http://www.sciencedirect.com/science/article/pii/S0161813X10000951
Grob, D. (1956). The Manifestations and Treatment of Poisoning Due to Nerve Gas and Other
Organic Phosphate Anticholinesterase Compounds. Archives of Internal Medicine, 98(2),
221-239. Retrieved from ISI:A1956WD52700010
Grob, D., & Harvey, A. M. (1953). The effects and treatment of nerve gas poisoning. The
American Journal of Medicine, 14(1), 52-63. doi:doi: 10.1016/0002-9343(53)90358-1.
Retrieved from http://www.sciencedirect.com/science/article/pii/0002934353903581
Harkany, T., Mulder, J., Horvath, K. M., Keijser, J., Van der Meeberg, E. K., Nyakas, C. et al.
(2001). Oral post-lesion administration of 5-HT(1A) receptor agonist repinotan
hydrochloride (Bay X 3702) attenuates NMDA-induced delayed neuronal death in rat
magnocellular nucleus basalis. Neuroscience, 108(4), 629-642. Retrieved from
ISI:000172937600008
Hogg, S. (1996). A review of the validity and variability of the elevated plus-maze as an animal
model of anxiety. Pharmacology Biochemistry and Behavior, 54(1), 21-30. Retrieved
from ISI:A1996UF99800004
Husain, K., Ansari, R. A., & Ferder, L. (2010). Pharmacological agents in the
prophylaxis/treatment of organophosphorous pesticide intoxication. Indian Journal of
Experimental Biology, 48(7), 642-650. Retrieved from ISI:000279595300005

59
	
  

	
  
	
  

Jimmerson, V. R., Shih, T. M., Maxwell, D. M., Kaminskis, A., & Mailman, R. B. (1989). The
effect of 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorin-2-oxide on tissue cholinesterase
and carboxylesterase activities of the rat. Fundamental and Applied Toxicology, 13(3),
568-575. doi:doi: 10.1016/0272-0590(89)90294-7. Retrieved from
http://www.sciencedirect.com/science/article/pii/0272059089902947
Joshi, K. V. (2009). Novel Neuroprotectants for Sarin plus CBDP induced convulsions. Masters
thesis, Wright State University. Retrieved from
http://rave.ohiolink.edu/etdc/view?acc_num=wright1253321185
Kadar, T., Shapira, S., Cohen, G., Sahar, R., Alkalay, D., & Raveh, L. (1995). Sarin-Induced
Neuropathology in Rats. Human & Experimental Toxicology, 14(3), 252-259. Retrieved
from ISI:A1995QQ39500005
Kamei, J., Igarashi, H., & Kasuya, Y. (1991). Modulation by Serotonin of Glutamate-Induced
Lethality in Mice. Research Communications in Chemical Pathology and Pharmacology,
74(2), 167-184. Retrieved from ISI:A1991GR58300004
Keyes, D. C. (2005). Chemical Nerve Agents. In J.L. Burstein, R. B. Schwartz, & R. E.
Swienton (Eds.), Medical response to terrorism : preparedness and clinical practice (pp.
2-15). Philadelphia, PA: Lippincott Williams & Wilkins.
Kline, A. E., Yu, J., Horvath, E., Marion, D. W., & Dixon, C. E. (2001). The selective 5-HT1a
receptor agonist repinotan HCL attenuates histopathology and spatial learning deficits
following traumatic brain injury in rats. Neuroscience, 106(3), 547-555. Retrieved from
ISI:000171640800006
Lemercier, G., Carpentier, P., Sentenacroumanou, H., & Morelis, P. (1983). Histological and
Histochemical-Changes in the Central Nervous-System of the Rat Poisoned by An

60
	
  

	
  
	
  

Irreversible Anti-Cholinesterase Organo-Phosphorus Compound. Acta Neuropathologica,
61(2), 123-129. Retrieved from ISI:A1983RG11700006
Mach, M., Grubbs, R. D., Price, W. A., Nagaoka, M., Dubovicky, M., & Lucot, J. B. (2008).
Delayed behavioral and endocrine effects of sarin and stress exposure in mice. Journal of
Applied Toxicology, 28(2), 132-139. Retrieved from ISI:000254212600005
Mamczarz, J., Pereira, E. F., Aracava, Y., Adler, M., & Albuquerque, E. X. (2010a). An acute
exposure to a sub-lethal dose of soman triggers anxiety-related behavior in guinea pigs:
interactions with acute restraint. Neurotoxicology, 31(1), 77-84. doi:S0161813X(09)00235-6 [pii];10.1016/j.neuro.2009.10.012 [doi]. Retrieved from PM:19883683
Mamczarz, J., Pereira, E. F. R., Aracava, Y., Adler, M., & Albuquerque, E. X. (2010b). An acute
exposure to a sub-lethal dose of soman triggers anxiety-related behavior in guinea pigs:
Interactions with acute restraint. Neurotoxicology, 31(1), 77-84. doi:doi:
10.1016/j.neuro.2009.10.012. Retrieved from
http://www.sciencedirect.com/science/article/pii/S0161813X09002356
Mauler, F., & Horvath, E. (2005). Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor
agonist, in animal models of stroke and traumatic brain injury. Journal of Cerebral Blood
Flow and Metabolism, 25(4), 451-459. Retrieved from ISI:000228274700005
McDonough, J. H., & Shih, T. M. (1997). Neuropharmacological mechanisms of nerve agentinduced seizure and neuropathology. Neuroscience and Biobehavioral Reviews, 21(5),
559-579. Retrieved from ISI:A1997YC28000003
McLin, J. P., & Steward, O. (2006). Comparison of seizure phenotype and neurodegeneration
induced by systemic kainic acid in inbred, outbred, and hybrid mouse strains. European
Journal of Neuroscience, 24, 2191-2202. doi:10.1111/j.1460-9568.2006.05111.x

61
	
  

	
  
	
  

Moser, V. C. (1995). Comparisons of the Acute Effects of Cholinesterase-Inhibitors Using A
Neurobehavioral Screening Battery in Rats. Neurotoxicology and Teratology, 17(6), 617625. Retrieved from ISI:A1995TJ69200003
Moser, V. C. (1990). Approaches for assessing the validity of a functional observational battery.
Neurotoxicology and Teratology, 12(5), 483-488. Retrieved from
http://journals.ohiolink.edu/ejc/article.cgi?issn=08920362&issue=v12i0005&article=483
_afatvoafob
Mullen, R. J., Buck, C. R., & Smith, A. M. (1992). Neun, A Neuronal Specific Nuclear-Protein
in Vertebrates. Development, 116(1), 201-211. Retrieved from ISI:A1992JQ86400019
Myhrer, T., Andersen, J. M., Nguyen, N. H., & Aas, P. (2005). Soman-induced convulsions in
rats terminated with pharmacological agents after 45 min: Neuropathology and cognitive
performance. Neurotoxicology, 26(1), 39-48. Retrieved from ISI:000225249000005
Myhrer, T., Enger, S., & Aas, P. (2007). Anticonvulsant effects of damage to structures involved
in seizure induction in rats exposed to soman. Neurotoxicology, 28(4), 819-828.
Retrieved from ISI:000248875500013
Nieminen, S. A., Lecklin, A., Heikkinen, O., & Ylitalo, P. (1990). Acute Behavioral-Effects of
the Organophosphates Sarin and Soman in Rats. Pharmacology & Toxicology, 67(1), 3640. Retrieved from ISI:A1990DV18100007
Olney, J. W., Labruyere, J., Wang, G., Wozniak, D. F., Price, M. T., & Sesma, M. A. (1991).
Nmda Antagonist Neurotoxicity - Mechanism and Prevention. Science, 254(5037), 15151518. Retrieved from ISI:A1991GT90300043
Olson, K. B. (1999). Aum Shinrikyo: Once and future threat? Emerging Infectious Diseases,
5(4), 513-516. Retrieved from ISI:000081988300009

62
	
  

	
  
	
  

Oosterink, B. J., Harkany, T., & Luiten, P. G. M. (2003). Post-lesion administration of 5-HT1A
receptor agonist 8-OH-DPAT protects cholinergic nucleus basalis neurons against
NMDA excitotoxicity. NeuroReport, 14(1). Retrieved from
http://journals.lww.com/neuroreport/Fulltext/2003/01200/Post_lesion_administration_of_
5_HT1A_receptor.11.aspx
Perry, K. & Fuller, R. (1989). Determination of brain concentrations of 8-hydroxy-2-(di-npropylamino)tetralin by liquid chromatography with electrochemical
detection. Biochemical Pharmacology, 38(19), 3169-73. Retrieved from
http://dx.doi.org/10.1016/0006-2952(89)90609-6
Peruche, B., Backhauß, C., Rehn, J., & Rieglstein, J. (1994). Protective effects of 5HT&lt;sub&gt;1A&lt;/sub&gt; receptor agonists against neuronal damage demonstrated
in vivo and in vitro. Journal of Neural Transmission: Parkinson's Disease and Dementia
Section, 8(1), 73-83. Retrieved from http://dx.doi.org/10.1007/BF02250918. Retrieved
from Springer Wien.
Prut, L., & Belzung, C. (2003). The open field as a paradigm to measure the effects of drugs on
anxiety-like behaviors: a review. European Journal of Pharmacology, 463(1-3), 3-33.
Retrieved from ISI:000181295800002
Ramos, A. J., Rubio, M. D., Defagot, C., Hischberg, L., Villar, M. J., & Brusco, A. (2004). The
5HT1A receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction
after ischemic damage caused by cortical devascularization. Brain Res., 1030(2), 201220. doi:S0006-8993(04)01663-4 [pii];10.1016/j.brainres.2004.10.019 [doi]. Retrieved
from PM:15571670

63
	
  

	
  
	
  

Rodgers, R. J., & Johnson, N. J. T. (1995). Factor-Analysis of Spatiotemporal and Ethological
Measures in the Murine Elevated Plus-Maze Test of Anxiety. Pharmacology
Biochemistry and Behavior, 52(2), 297-303. Retrieved from ISI:A1995RQ90400009
Savolainen, K. (2001). Understanding the Toxic Actions of Organophosphates. In R. Kreiger, J.
Doull, D. Ecobichon, D. Gammon, E. Hodgson, L. Reiter, & J. Ross (Eds.), Handbook of
Pesticide Toxicology (pp. 1013-1042). San Diego, CA: Academic Press.
Shih, T. M., & Romano, J. A. (1988). The Effects of Choline on Soman-Induced Analgesia and
Toxicity. Neurotoxicology and Teratology, 10(4), 287-294. Retrieved from
ISI:A1988Q514100002
Sidell, F. R. (1994). Clinical Effects of Organophosphorus Cholinesterase-Inhibitors. Journal of
Applied Toxicology, 14(2), 111-113. Retrieved from ISI:A1994NG93900009
Sidell, F. R., Newmark, J., & McDonough, J. H. (2008). Nerve Agents. In S. Tuorinsky (Ed.),
Medical Aspects of Chemical Warfare (pp. 155-219). Washington, DC: Office of The
Surgeon General Department of the Army, United States of America.
Smolen, A., Smolen, T. N., Wehner, J. M., & Collins, A. C. (1985). Genetically determined
differences in acute responses to diisopropylfluorophosphate.
Pharmacol.Biochem.Behav., 22(4), 623-630. Retrieved from PM:3991771
Solberg, Y., & Belkin, M. (1997). The role of excitotoxicity in organophosphorous nerve agents
central poisoning. Trends in Pharmacological Sciences, 18(6), 183-185. doi:doi:
10.1016/S0165-6147(97)89540-5. Retrieved from
http://www.sciencedirect.com/science/article/pii/S0165614797895405

64
	
  

	
  
	
  

Stojiljkovic, M. P., & Jokanovic, M. (2006). Pyridinium oximes: rationale for their selection as
causal antidotes against organophosphate poisonings and current solutions for autoinjectors. Arh.Hig.Rada Toksikol., 57(4), 435-443. Retrieved from PM:17265683
Tang, F. R., Loke, W. K., & Ling, E. A. (2011). Comparison of Status Epilepticus Models
Induced by Pilocarpine and Nerve Agents A Systematic Review of the Underlying
Aetiology and Adopted Therapeutic Approaches. Current Medicinal Chemistry, 18(6),
886-899. Retrieved from ISI:000288989200006
Tattersall, J. (2009). Seizure activity post organophosphate exposure. Frontiers in Bioscience,
14, 3688-3711. Retrieved from ISI:000262352400254
Tfelt-Hansen, P., de Vries, P., & Saxena, P. R. (2000). Triptans in Migraine: A Comparative
Review of Pharmacology, Pharmacokinetics and Efficacy. Drugs, 60(6), 1259-1287.
Retrieved from
http://journals.ohiolink.edu/ejc/article.cgi?issn=00126667&issue=v60i0006&article=125
9_timacroppae
U.S.Army Medical Research Institute of Chemical Defense. (2007). Medical management of
chemical casualties: Handbook (4th ed.). Aberdeen Proving Ground, MD: USAMRICD,
MCMR-CDM.
Walf, A. A., & Frye, C. A. (2007). The use of the elevated plus maze as an assay of anxietyrelated behavior in rodents. Nature Protocols, 2(2), 322-328. Retrieved from
ISI:000253138100012
Weinbroum, A. A. (2004). Pathophysiological and clinical aspects of combat anticholinesterase
poisoning. British Medical Bulletin, 72(1), 119-133. Retrieved from
http://bmb.oxfordjournals.org/content/72/1/119.abstract

65
	
  

	
  
	
  

Weissman, B. A., & Raveh, L. (2008). Therapy against organophosphate poisoning: The
importance of anticholinergic drugs with antiglutamatergic properties. Toxicology and
Applied Pharmacology, 232(2), 351-358. Retrieved from ISI:000260290000021
Wheelock, C. E., Phillips, B. M., Anderson, B. S., Miller, J. L., Miller, M. J., & Hammock, B. D.
(2008). Applications of carboxylesterase activity in environmental monitoring and
toxicity identification evaluations (TIEs). Reviews of Environmental Contamination and
Toxicology, Vol 195, 195, 117-178. Retrieved from ISI:000254415800005
Wiener, S. W., & Hoffman, R. S. (2004). Nerve Agents: A Comprehensive Review. Journal of
Intensive Care Medicine, 19(1), 22-37. Retrieved from
http://journals.ohiolink.edu/ejc/article.cgi?issn=08850666&issue=v19i0001&article=22_
naacr
Zimmer, L. A., Ennis, M., & Shipley, M. T. (1997). Soman-induced seizures rapidly activate
astrocytes and microglia in discrete brain regions. Journal of Comparative Neurology,
378(4), 482-492. Retrieved from ISI:A1997WF85700004

66
	
  

